Welcome to our dedicated page for Zentek news (Ticker: ZTEK), a resource for investors and traders seeking the latest updates and insights on Zentek stock.
Zentek Ltd. develops and commercializes graphene-enabled and advanced material technologies through platforms that include ZenGUARD™, Albany Graphite and Triera. Company developments center on ZenGUARD™ enhanced air filters and related regulatory classification, commercialization pathways and HVAC supply-chain opportunities.
Recurring updates also cover the Albany Graphite Project in Ontario, including technical studies, environmental and social baseline work, market analysis and high-purity graphite positioning for nuclear, defence, battery and industrial markets. Triera Biosciences updates focus on aptamer discovery, biosensor enablement, machine-learning classification and infectious-disease applications, alongside material agreements, capital-structure disclosure, governance matters and operating results.
Zentek Ltd. (Nasdaq:ZTEK) announced the publication of its international patent application for ZenGUARD technology by the World Intellectual Property Office. This milestone reflects the company’s progress from scientific breakthrough to commercialization. The ZenGUARD technology, which exhibits 99% antimicrobial activity, including effectiveness against COVID-19, aims to enhance revenue potential through commercial opportunities. Zentek is scaling production in its Guelph facility and actively pursuing market opportunities for ZenGUARD, particularly in transmission prevention with coated masks.
Zentek Ltd. (NASDAQ:ZTEK; TSX-V:ZEN; OTC PINK:ZENYF) announced its SEC Form 40-F registration statement is effective, and its common stock will start trading on the Nasdaq Capital Market under the symbol ZTEK on March 22, 2022. CEO Greg Fenton stated this milestone will enhance liquidity, attract U.S. investors, and increase visibility. Zentek focuses on next-gen healthcare solutions, including ZenGUARD™, an antimicrobial coating with 99% efficacy against COVID-19, and an exclusive partnership for rapid pathogen detection technology.